LUMAKRAS vs ZEGFROVY

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. LUMAKRAS and ZEGFROVY are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	LUMAKRAS	ZEGFROVY
Rating	72/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	SOTORASIB	SUNVOZERTINIB
Manufacturer	Amgen Inc	Dizal Jiangsu
Dosage forms	Tablet	Tablet
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma	Non-Small-Cell Lung Carcinoma

lumakras zegfrovy

Rating

72/100

New

Pharmacy pays

—

Type

Active ingredient

SOTORASIB

SUNVOZERTINIB

Manufacturer

Amgen Inc

Dizal Jiangsu

Dosage forms

Tablet

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Lumakras and Zegfrovy?

Lumakras contains Sotorasib, while Zegfrovy contains Sunvozertinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.